Prevalence and Severity Distribution of Type 2 Inflammation-Related Comorbidities Among Patients with Asthma, Chronic Rhinosinusitis with Nasal Polyps, and Atopic Dermatitis.

"Declarations Competing interestsAHK, IG, and RJ are employees of Sanofi and own stock and/or stock options in the company. SK is an employee of Regeneron Pharmaceuticals, Inc. and owns stock and/or stock options in the company. MS and JS are employees of Adelphi Real World, a company that received research funding for the study. Ethical ApprovalIn line with Adelphi Real World Standard Operating Procedures, each Disease-Specific Programme was submitted to the Western Institutional Review Board, a central institutional review board, where ethical exemption determination was granted. Consent to ParticipateAll included patients provided informed consent to participate in the study. Consent to PublishNot applicable. Competing interests AHK, IG, and RJ are employees of Sanofi and own stock and/or stock options in the company. SK is an employee of Regeneron Pharmaceuticals, Inc. and owns stock and/or stock options in the company. MS and JS are employees of Adelphi Real World, a company that received research funding for the study."

"Funding This study was an analysis of data collected as part of the Adelphi Real World Asthma, CRSwNP and AD Disease-Specific Programmes, for which Sanofi provided financial support as a subscriber."